SCHEMBL4055877

SCHEMBL4055877

CN(C)CCCCN1c2ccccc2N(c2ccc(F)cc2Cl)S1(=O)=O

nearest known ligand 0.48

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 19/20 0.48
SLC6A4 P31645 7/20 0.48
SLC6A3 Q01959 10/20 0.46
KCNH2 Q12809 1/20 0.44
ACHE P22303 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4062353 0.99 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KCNH2ACHE
SCHEMBL4054010 0.99 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KCNH2ACHE
Hydrochloric Acid SCHEMBL4065542 0.98 SLC6A2 (0.47) SLC6A2SLC6A4SLC6A3KCNH2ACHE
SCHEMBL4945760 0.89 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4058150 0.88 SLC6A2 (0.57) SLC6A2SLC6A4SLC6A3KCNH2
Hydrochloric Acid SCHEMBL4944129 0.88 SLC6A2 (0.57) SLC6A2SLC6A4SLC6A3KCNH2
Hydrochloric Acid SCHEMBL4945021 0.87 SLC6A2 (0.56) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL4055875 0.87 ACHE (0.36) SLC6A2SLC6A4SLC6A3KCNH2ACHE
SCHEMBL3612861 0.86 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3KCNH2ACHE
Hydrochloric Acid SCHEMBL4062357 0.86 ACHE (0.38) SLC6A2SLC6A4SLC6A3KCNH2ACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP claimed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US claimed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO claimed
EP-2061776-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE Wyeth a Corporation of the State of Delaware (US) 2009-05-27 EP disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-03 US disclosed
WO-2008073459-A1 ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161366-A1 AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 SLC6A2 2/4885SLC6A4 1/4885SLC6A3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.